ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $83.00 at Raymond James

ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) had its price objective lifted by Raymond James from $81.00 to $83.00 in a research report sent to investors on Wednesday, Benzinga reports. They currently have an outperform rating on the specialty pharmaceutical company's stock.

Several other analysts have also recently issued reports on ANIP. HC Wainwright reaffirmed a buy rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday. StockNews.com downgraded ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, September 7th. Finally, Truist Financial reiterated a hold rating and issued a $60.00 target price (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $78.80.

ANI Pharmaceuticals Stock Up 1.6 %

Shares of ANI Pharmaceuticals stock traded up $0.99 during trading on Wednesday, hitting $61.05. 364,546 shares of the stock traded hands, compared to its average volume of 207,347. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The stock's fifty day simple moving average is $61.25 and its 200 day simple moving average is $63.80. The firm has a market cap of $1.28 billion, a P/E ratio of 38.41 and a beta of 0.71. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same quarter last year, the firm posted $1.06 EPS. The company's revenue for the quarter was up 18.5% on a year-over-year basis. On average, equities analysts predict that ANI Pharmaceuticals will post 3.5 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 20,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $58.90, for a total value of $1,178,000.00. Following the completion of the sale, the chief operating officer now directly owns 682,620 shares in the company, valued at approximately $40,206,318. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 66,007 shares of company stock valued at $4,089,790 in the last ninety days. Corporate insiders own 12.70% of the company's stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP increased its holdings in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company's stock valued at $62,032,000 after purchasing an additional 277,989 shares during the period. Millennium Management LLC increased its holdings in ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock worth $14,651,000 after buying an additional 209,272 shares during the period. American Century Companies Inc. raised its position in ANI Pharmaceuticals by 99.2% during the 2nd quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company's stock worth $6,357,000 after buying an additional 49,717 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in ANI Pharmaceuticals by 6.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company's stock valued at $32,628,000 after acquiring an additional 33,359 shares during the period. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $2,218,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.